Rivia is a technology company building a data engine that powers the future of clinical trial intelligence. Rivia was founded on the belief that new drugs can be brought to market more successfully with a fraction of today's capital.
Over the past two years, European and US based biotechs running global clinical trials on Rivia have demonstrated measurable impact, from earlier understanding of therapeutic potential to significantly more efficient trial execution. In March 2026, Rivia raised its $15M Series A led by Earlybird Venture Capital.
Rivia’s ambition is to become the standard infrastructure for modern drug development, transforming how trials are executed end-to-end.